Product news from the 08/22/06 News Brief

Share this article:
Oscient Pharmaceuticals has completed its acquisition of the US rights to the cardiovascular product Antara 130 mg (fenofibrate) capsules from Reliant Pharmaceuticals. Antara will be commercialized by Oscient's national sales force beginning later this week. Bristol-Myers Squibb and Otsuka Pharmaceutical have launched Abilify Discmelt (aripiprazole) orally disintegrating tablets, a new oral form of the antipsychotic medication Abilify (aripiprazole) that disintegrates rapidly in the mouth. The FDA approved Abilify Discmelt in June.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.